AIM: Stable gastric pentadecapeptide BPC 157, administered before a high-dose magnesium injection in rats, might be a useful peptide therapy against magnesium toxicity and the magnesium-induced effect on cell depolarization. Moreover, this might be an NO-system-related effect. Previously, BPC 157 counteracts paralysis, arrhythmias and hyperkalaemia, extreme muscle weakness; parasympathetic and neuromuscular blockade; injured muscle healing and interacts with the NOS-blocker and NOS-substrate effects. MAIN METHODS: Assessment included magnesium sulfate (560 mg/kg intraperitoneally)-induced muscle weakness, muscle and brain lesions, hypermagnesemia, hyperkalaemia, increased serum enzyme values assessed in rats during and at the end of a 30-min period and medication (given intraperitoneally/kg at 15 min before magnesium) [BPC 157 (10 µg, 10 ng), L-NAME (5 mg), L-arginine (100 mg), alone and/or together]. In HEK293 cells, the increasing magnesium concentration from 1 to 5 mM could depolarize the cells at 1.75 ± 0.44 mV. KEY FINDINGS: L-NAME + magnesium-rats and L-arginine + magnesium-rats exhibited worsened severe muscle weakness and lesions, brain lesions, hypermagnesemia and serum enzymes values, with emerging hyperkalaemia. However, L-NAME + L-arginine + magnesium-rats exhibited all control values and normokalaemia. BPC 157 abrogated hypermagnesemia and counteracted all of the magnesium-induced disturbances (including those aggravated by L-NAME or L-arginine). Thus, cell depolarization due to increasing magnesium concentration was inhibited in the presence of BPC 157 (1 µM) in vitro. SIGNIFICANCE: BPC 157 likely counteracts the initial event leading to hypermagnesemia and the life-threatening actions after a magnesium overdose. In contrast, a worsened clinical course, higher hypermagnesemia, and emerging hyperkalaemia might cause both L-NAME and L-arginine to affect the same events adversely. These events were also opposed by BPC 157.
AIM: Stable gastric pentadecapeptide BPC 157, administered before a high-dose magnesium injection in rats, might be a useful peptide therapy against magnesiumtoxicity and the magnesium-induced effect on cell depolarization. Moreover, this might be an NO-system-related effect. Previously, BPC 157 counteracts paralysis, arrhythmias and hyperkalaemia, extreme muscle weakness; parasympathetic and neuromuscular blockade; injured muscle healing and interacts with the NOS-blocker and NOS-substrate effects. MAIN METHODS: Assessment included magnesium sulfate (560 mg/kg intraperitoneally)-induced muscle weakness, muscle and brain lesions, hypermagnesemia, hyperkalaemia, increased serum enzyme values assessed in rats during and at the end of a 30-min period and medication (given intraperitoneally/kg at 15 min before magnesium) [BPC 157 (10 µg, 10 ng), L-NAME (5 mg), L-arginine (100 mg), alone and/or together]. In HEK293 cells, the increasing magnesium concentration from 1 to 5 mM could depolarize the cells at 1.75 ± 0.44 mV. KEY FINDINGS:L-NAME + magnesium-rats and L-arginine + magnesium-rats exhibited worsened severe muscle weakness and lesions, brain lesions, hypermagnesemia and serum enzymes values, with emerging hyperkalaemia. However, L-NAME + L-arginine + magnesium-rats exhibited all control values and normokalaemia. BPC 157 abrogated hypermagnesemia and counteracted all of the magnesium-induced disturbances (including those aggravated by L-NAME or L-arginine). Thus, cell depolarization due to increasing magnesium concentration was inhibited in the presence of BPC 157 (1 µM) in vitro. SIGNIFICANCE: BPC 157 likely counteracts the initial event leading to hypermagnesemia and the life-threatening actions after a magnesiumoverdose. In contrast, a worsened clinical course, higher hypermagnesemia, and emerging hyperkalaemia might cause both L-NAME and L-arginine to affect the same events adversely. These events were also opposed by BPC 157.
Authors: Danira Pevec; Tomislav Novinscak; Luka Brcic; Kristijan Sipos; Ivana Jukic; Mario Staresinic; Sandro Mise; Iva Brcic; Danijela Kolenc; Robert Klicek; Tihomir Banic; Marko Sever; Ana Kocijan; Lidija Berkopic; Bozo Radic; Gojko Buljat; Tomislav Anic; Ivan Zoricic; Ivan Bojanic; Sven Seiwerth; Predrag Sikiric Journal: Med Sci Monit Date: 2010-03
Authors: S Manzo-Avalos; V Pérez-Vázquez; J Ramírez; L Aguilera-Aguirre; J C González-Hernández; M Clemente-Guerrero; R Villalobos-Molina; A Saavedra-Molina Journal: Amino Acids Date: 2002-06 Impact factor: 3.520
Authors: Predrag Sikiric; Ki-Baik Hahm; Alenka Boban Blagaic; Ante Tvrdeic; Katarina Horvat Pavlov; Andrea Petrovic; Antonio Kokot; Slaven Gojkovic; Ivan Krezic; Domagoj Drmic; Rudolf Rucman; Sven Seiwerth Journal: Gut Liver Date: 2020-03-15 Impact factor: 4.519
Authors: Sven Seiwerth; Marija Milavic; Jaksa Vukojevic; Slaven Gojkovic; Ivan Krezic; Lovorka Batelja Vuletic; Katarina Horvat Pavlov; Andrea Petrovic; Suncana Sikiric; Hrvoje Vranes; Andreja Prtoric; Helena Zizek; Tajana Durasin; Ivan Dobric; Mario Staresinic; Sanja Strbe; Mario Knezevic; Marija Sola; Antonio Kokot; Marko Sever; Eva Lovric; Anita Skrtic; Alenka Boban Blagaic; Predrag Sikiric Journal: Front Pharmacol Date: 2021-06-29 Impact factor: 5.810
Authors: Slaven Gojkovic; Ivan Krezic; Hrvoje Vranes; Helena Zizek; Domagoj Drmic; Katarina Horvat Pavlov; Andrea Petrovic; Lovorka Batelja Vuletic; Marija Milavic; Suncana Sikiric; Irma Stilinovic; Mariam Samara; Mario Knezevic; Ivan Barisic; Ivica Sjekavica; Eva Lovric; Anita Skrtic; Sven Seiwerth; Predrag Sikiric Journal: Biomedicines Date: 2021-06-28